Report of Foreign Issuer (6-k)
July 08 2020 - 7:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of
1934
For the month of July 2020
Commission File Number: 001-37643
KITOV PHARMA LTD.
(Translation of registrant’s name
into English)
One Azrieli Center, Round Tower, Tel
Aviv 6701101, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will
file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the Registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the Registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On July 8, 2020, Kitov Pharma Ltd. (the
“Company” or the “Registrant”) issued a press release, “Kitov Pharma Receives Notice of Intention
to Grant a European Patent Covering CM24, its anti-CEACAM1 Antibody”, which is attached hereto as Exhibit 99.1.
Exhibits
Incorporation
by Reference
This Form 6-K, including all exhibits
attached hereto, is hereby incorporated by reference into each of the Registrant’s Registration Statements on Form F-3 filed with the SEC on December 12, 2016 (Registration file numbers 333-207117 and 333-211477), the
Registrant’s Registration Statement on Form S-8 filed with the SEC on May 20, 2016 (Registration file number
333-211478), the Registrant’s Registration Statement on Form S-8 filed with the SEC on June 6, 2017 (Registration
file number 333-218538), the Registrant’s Registration Statement on Form F-3, as amended, originally filed with the SEC
on July 16, 2018 (Registration file number 333-226195), the Registrant’s Registration Statement on Form S-8 filed with the SEC on March 28, 2019 (Registration file number 333-230584), the Registrant’s Registration
Statement on Form F-3 filed with the SEC on September 16, 2019 (Registration file number 333-233795), the
Registrant’s Registration Statement on Form F-3 filed with the SEC on December 2, 2019 (Registration file
number 333-235327), the Registrant’s Registration Statement on Form F-3 filed with the SEC on May 13, 2020
(Registration file number 333- 238229), and the Registrant’s Registration Statement on Form S-8 filed with
the SEC on May 18, 2020 (Registration file number 333-238481), to be a part thereof from the date on which this report
is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
July 8, 2020
|
KITOV PHARMA LTD.
|
|
|
|
|
By:
|
/s/ Isaac Israel
|
|
|
Isaac Israel
|
|
|
Chief Executive Officer
|
2
Kitov Pharma (NASDAQ:KTOVW)
Historical Stock Chart
From Sep 2024 to Oct 2024
Kitov Pharma (NASDAQ:KTOVW)
Historical Stock Chart
From Oct 2023 to Oct 2024